|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0013216,
umls-concept:C0024501,
umls-concept:C0055982,
umls-concept:C0178602,
umls-concept:C0183683,
umls-concept:C0205345,
umls-concept:C0344211,
umls-concept:C0439228,
umls-concept:C0522510,
umls-concept:C0721534,
umls-concept:C1136535,
umls-concept:C1171411,
umls-concept:C1317973,
umls-concept:C1516213,
umls-concept:C1521721,
umls-concept:C1524063
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2010-1-4
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
In several commonly used regimens, chemotherapy doses are split across different days of the cycle. We aimed to determine the feasibility of growth factor support with once-per-cycle pegfilgrastim in this setting.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1699-3055
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
842-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20045791-Adult,
pubmed-meshheading:20045791-Aged,
pubmed-meshheading:20045791-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20045791-Breast Neoplasms,
pubmed-meshheading:20045791-Breast Neoplasms, Male,
pubmed-meshheading:20045791-Carcinoma,
pubmed-meshheading:20045791-Chemotherapy, Adjuvant,
pubmed-meshheading:20045791-Cyclophosphamide,
pubmed-meshheading:20045791-Dose-Response Relationship, Drug,
pubmed-meshheading:20045791-Drug Administration Schedule,
pubmed-meshheading:20045791-Female,
pubmed-meshheading:20045791-Fluorouracil,
pubmed-meshheading:20045791-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:20045791-Humans,
pubmed-meshheading:20045791-Injections, Intravenous,
pubmed-meshheading:20045791-Male,
pubmed-meshheading:20045791-Methotrexate,
pubmed-meshheading:20045791-Middle Aged,
pubmed-meshheading:20045791-Neutropenia,
pubmed-meshheading:20045791-Recombinant Proteins,
pubmed-meshheading:20045791-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen.
|
|
pubmed:affiliation |
U.O. di Oncologia, Ospedale S. Croce, Fano, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
